Interesting quote. I hadn't listened the CC or read the transcript. I tend to think SK is a straight shooter if somewhat rosy-eyed. Still, I find his reason for reporting -- that the timing "makes it difficult to hold onto the information for a conference" -- less than compelling. I'm sure he means it. But how many biotechs find a way to hold onto their results until ASCO? (Every single one of them that has a submission accepted.) Strange statement. I mean, they're professionals, right? The data is double-blind. They control it. Mulling...
Market Data 
Markets 
AI
